| Treatment group |
||||
|---|---|---|---|---|
| Oral MXF (n = 7913) | Comparator (n = 7603) | Sequential MXF (n = 2535) | Comparator (n = 2574) | |
| Total deaths | 21 (0.27%) | 27 (0.36%) | 98 (3.87%) | 103 (4.0%) |
| Deaths within 2 days of treatment start | 1 (0.01%) | 3 (0.04%) | 8 (0.32%) | 11 (0.43%) |
| Deaths within 3 days of stopping study medication | 7 (0.09%) | 11 (0.14%) | 36 (1.42%) | 46 (1.79%) |
| Death and adverse event considered as a clinically-relevant outcome of QTc prolongation | 5 (0.06%) | 4 (0.05%) | 10 (0.39%) | 15 (0.58%) |
| Adverse events considered as clinically relevant outcome of QTc prolongation | 20 (0.25%) | 16 (0.21%) | 27 (1.07%) | 29 (1.13%) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.